Viral vectors, such as adeno-associated viruses (AAV) and lentiviral viruses (LVV), are recently at the forefront of biotherapeutic development for the support of cell and gene therapies. As with ...
In order for HIV to replicate, the viral genome must enter into the cell nucleus and integrate into the host cell chromosome. Previous work suggests that the entry proceeds through nuclear pore ...
Significant variability exists in adeno-associated virus (AAV) measurement methods, especially with polymerase chain reaction-enzyme linked immunosorbent assay (PCR-ELISA), highlighting the need for ...
The FDA granted priority review, with a decision expected by June 19, 2025. LEN represents a novel class of HIV therapies by targeting the viral capsid, a multifunctional protein essential for HIV ...
Data from a disease model showed that HSV1 infection caused tau hyperphosphorylation, forming aggregates that trapped viral ...
Key PointsResearch on HIV's conical capsid that began over 25 years ago led to the development of lenacapavir, the world's ...
A computational model of the more than 26 million atoms in a DNA-packed viral capsid expands our understanding of virus structure and DNA dynamics, insights that could provide new research avenues and ...
- Agreement grants Astellas rights to employ Sangamo’s novel proprietary capsid, STAC-BBB, for up to five potential neurological disease targets - Sangamo to receive a $20 million upfront license fee ...
Gilead Sciences announced a significant milestone: the U.S. FDA accepted their New Drug Applications (NDAs) for lenacapavir (LEN), a groundbreaking twice-yearly injectable HIV-1 capsid inhibitor for ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback